ADTRALZA

This brand name is authorized in Croatia, Estonia, Ireland, Japan, Lithuania, Poland, Romania, UK.

Active ingredients

The drug ADTRALZA contains one active pharmaceutical ingredient (API):

1	Tralokinumab UNII GK1LYB375A - TRALOKINUMAB
	Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds to the type 2 cytokine interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptors. Tralokinumab neutralises the biological activity of IL-13 by blocking its interaction with the IL-13Rα1/IL-4Rα receptor complex. IL-13 is a major driver of human type 2 inflammatory disease, such as atopic dermatitis and inhibiting the IL-13 pathway with tralokinumab in patients decreases many of the mediators of type 2 inflammation.
	Read more about Tralokinumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ADTRALZA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D11AH07		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1852310, 1852321, 1852332
GB	Medicines & Healthcare Products Regulatory Agency	399359
JP	医薬品医療機器総合機構	4490409G1022
LT	Valstybinė vaistų kontrolės tarnyba	1092843, 1092844, 1092845
PL	Rejestru Produktów Leczniczych	100455323
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68078001, W68078002, W68078003